Gujarat Themis Biosyn Approves Preferential Issue of ₹335 Crore Equity Shares
Gujarat Themis Biosyn approved a preferential issue of up to 82,10,786 equity shares at ₹408 each, raising approximately ₹335 crore. The funds will be raised via private placement from up to 5 investors, including promoter group entity Pharmaceutical Business Group (India) Limited.
The preferential issue involves a substantial amount of capital (₹335 crore) and the issuance of a significant number of equity shares, which will have a material impact on the company's capital structure and potentially its future growth trajectory.
The company is undertaking a significant preferential issue, indicating a capital infusion which is generally positive for growth and operations.
Gujarat Themis Biosyn Limited announced the outcome of its Board Meeting held on September 1, 2026. The Board has approved the issuance of up to 82,10,786 fully paid-up equity shares of face value ₹1 each at an issue price of ₹408 per share, including a securities premium of ₹407. This preferential issue, to be conducted on a private placement basis, will aggregate up to ₹335,00,00,688.
The proposed allottees include Pharmaceutical Business Group (India) Limited (Promoter group) for 61,27,453 shares, aggregating ₹250,00,00,824. Other allottees are Yusuf Khwaja Hamied (2,45,100 shares for ₹10,00,00,800), Special Situation India Fund (4,59,558 shares for ₹18,74,99,664), India Special Assets Fund III (6,83,823 shares for ₹27,89,99,784), and ISAF III Onshore Fund (6,94,852 shares for ₹28,34,99,616). Investors mentioned from serial number 2 to 5 belong to non-promoter/non-promoter group. The issuance is subject to necessary approvals, including those from shareholders and stock exchanges.
The Board meeting commenced at 2:30 p.m. and concluded at 3:35 p.m. on September 1, 2026.
A plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.